FR2306707B1 - - Google Patents

Info

Publication number
FR2306707B1
FR2306707B1 FR7610632A FR7610632A FR2306707B1 FR 2306707 B1 FR2306707 B1 FR 2306707B1 FR 7610632 A FR7610632 A FR 7610632A FR 7610632 A FR7610632 A FR 7610632A FR 2306707 B1 FR2306707 B1 FR 2306707B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7610632A
Other languages
French (fr)
Other versions
FR2306707A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of FR2306707A1 publication Critical patent/FR2306707A1/fr
Application granted granted Critical
Publication of FR2306707B1 publication Critical patent/FR2306707B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/915—Method or apparatus for preparing biological material
    • Y10S623/916—Blood vessel

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
FR7610632A 1975-04-10 1976-04-12 Perfectionnements aux greffes de tissus animaux Granted FR2306707A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL47062A IL47062A (en) 1975-04-10 1975-04-10 Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde

Publications (2)

Publication Number Publication Date
FR2306707A1 FR2306707A1 (fr) 1976-11-05
FR2306707B1 true FR2306707B1 (OSRAM) 1979-03-23

Family

ID=11048169

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7610632A Granted FR2306707A1 (fr) 1975-04-10 1976-04-12 Perfectionnements aux greffes de tissus animaux

Country Status (6)

Country Link
US (1) US4120649A (OSRAM)
JP (1) JPS51124094A (OSRAM)
DE (1) DE2614873A1 (OSRAM)
FR (1) FR2306707A1 (OSRAM)
GB (1) GB1527152A (OSRAM)
IL (1) IL47062A (OSRAM)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56112907A (en) * 1980-02-12 1981-09-05 Japan Atom Energy Res Inst Production of polymer composition including bioactive substance
US4466139A (en) * 1980-07-01 1984-08-21 Vettivetpillai Ketharanathan Vascular prostheses
US4378224A (en) * 1980-09-19 1983-03-29 Nimni Marcel E Coating for bioprosthetic device and method of making same
US4388735A (en) * 1980-11-03 1983-06-21 Shiley Inc. Low profile prosthetic xenograft heart valve
US4384374A (en) * 1981-03-27 1983-05-24 Muldashev Ernst R Homotransplant for layer-by-layer keratoplasty
US4372743A (en) * 1981-06-22 1983-02-08 American Hospital Supply Corp. Low-pressure fixation of valvular tissue intended for implantation
FR2510598A1 (fr) * 1981-07-30 1983-02-04 Inst Francais Du Petrole Utilisation d'additifs azotes comme agents d'abaissement du point de trouble des distillats moyens d'hydrocarbures et compositions de distillats moyens d'hydrocarbures renfermant lesdits additifs
US4481009A (en) * 1982-05-13 1984-11-06 American Hospital Supply Corporation Polymer incorporation into implantable biological tissue to inhibit calcification
US4801299A (en) * 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
ZA843751B (en) * 1983-06-10 1984-12-24 University Patents Inc Body implants of extracellular matrix and means and methods of making and using such implants
US4681588A (en) * 1983-10-20 1987-07-21 Vettivetpillai Ketharanathan Biomaterial
US4553974A (en) * 1984-08-14 1985-11-19 Mayo Foundation Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4729139A (en) * 1985-11-05 1988-03-08 Baxter Travenol Selective incorporation of a polymer into implantable biological tissue to inhibit calcification
US4770665A (en) * 1985-11-05 1988-09-13 American Hospital Supply Corporation Elastomeric polymer incorporation into implantable biological tissue to inhibit calcification
AU586718B2 (en) * 1985-11-13 1989-07-20 Domedica Pty. Limited Treatment of collagenous tissue
US4786287A (en) * 1986-10-10 1988-11-22 Baxter Travenol Laboratories Process for decreasing residual aldehyde levels in implantable bioprosthetic tissue
US4813964A (en) * 1986-10-14 1989-03-21 Hancock Jaffe Laboratories Crosslinked anisotropic xenogeneic diaphragm tissue in flexor tendon pulley reconstruction
US5139527A (en) * 1987-12-17 1992-08-18 Immuno Aktiengesellschaft Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation
DE68914384T2 (de) * 1988-02-03 1994-07-28 Biomedical Design Inc Verhütung der kalzifizierung einer prothese.
AT398276B (de) * 1989-05-31 1994-11-25 Sorin Biomedica Spa Verfahren zur präparierung von biologischem implantationsmaterial
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US5374539A (en) * 1991-06-17 1994-12-20 Nimni; Marcel E. Process for purifying collagen and generating bioprosthesis
RU94028108A (ru) * 1991-11-26 1996-06-20 Рисерч Дивелопмент Фаундейшн (US) Трансплантант, способ восстановления функционирования нерва, способ замены кровеносного сосуда
US5342387A (en) * 1992-06-18 1994-08-30 American Biomed, Inc. Artificial support for a blood vessel
US5437287A (en) * 1992-08-17 1995-08-01 Carbomedics, Inc. Sterilization of tissue implants using iodine
JPH08511266A (ja) * 1993-06-07 1996-11-26 アメリカ合衆国 Ｍｈｃクラス▲ｉ▼抑制剤の自己免疫疾患及び移植拒絶治療への使用
US6203755B1 (en) 1994-03-04 2001-03-20 St. Jude Medical, Inc. Electron beam sterilization of biological tissues
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
US5595571A (en) * 1994-04-18 1997-01-21 Hancock Jaffe Laboratories Biological material pre-fixation treatment
WO1996004028A1 (en) 1994-07-29 1996-02-15 Baxter International Inc. Methods for treating implantable biological tissues to mitigate the calcification thereof and bioprosthetic articles treated by such methods
US5931969A (en) * 1994-07-29 1999-08-03 Baxter International Inc. Methods and apparatuses for treating biological tissue to mitigate calcification
USRE40570E1 (en) 1994-07-29 2008-11-11 Edwards Lifesciences Corporation Apparatuses and methods for treating biological tissue to mitigate calcification
US5782931A (en) * 1996-07-30 1998-07-21 Baxter International Inc. Methods for mitigating calcification and improving durability in glutaraldehyde-fixed bioprostheses and articles manufactured by such methods
US6152142A (en) * 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
US5891196A (en) * 1997-04-16 1999-04-06 Baxter International Inc. Method for actively binding heparin to crosslinked biological tissues
US5958669A (en) * 1997-05-02 1999-09-28 St. Jude Medical, Inc. Apparatus and method for crosslinking to fix tissue or crosslink molecules to tissue
US6008292A (en) * 1997-12-02 1999-12-28 Baxter International Inc. Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials
US6214054B1 (en) * 1998-09-21 2001-04-10 Edwards Lifesciences Corporation Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby
US6214055B1 (en) * 1998-10-30 2001-04-10 Mures Cardiovascular Research, Inc. Method and kit for rapid preparation of autologous tissue medical devices
US6524339B1 (en) 1999-01-27 2003-02-25 David H. Adams Cryopreserved homografts and other stentless bioprosthetic heart valves having natural tissue sewing rings
US6471723B1 (en) 2000-01-10 2002-10-29 St. Jude Medical, Inc. Biocompatible prosthetic tissue
PT1276431E (pt) * 2000-04-27 2006-11-30 Ray Jui-Fang Tsai Método para a expansão de células estaminais epiteliais
CA2411102A1 (en) 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
CZ20031380A3 (cs) * 2000-11-28 2003-10-15 Genentech, Inc. LFA-1 Antagonistické sloučeniny
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
IL157145A0 (en) 2001-01-31 2004-02-08 Idec Pharma Corp Use of dc23 antagonists for the treatment of neoplastic disorders
US6878168B2 (en) 2002-01-03 2005-04-12 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8308797B2 (en) 2002-01-04 2012-11-13 Colibri Heart Valve, LLC Percutaneously implantable replacement heart valve device and method of making same
CN1705439A (zh) * 2002-04-12 2005-12-07 细胞基因公司 干细胞和祖细胞分化的调节、鉴定及其应用
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
NZ587776A (en) 2003-04-09 2012-03-30 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
EP1742660A2 (en) * 2004-04-16 2007-01-17 Genentech, Inc. Treatment of disorders
RU2006140377A (ru) * 2004-04-16 2008-05-27 Дженентек, Инк. (Us) Способ усиления уничтожения в-клеток
MY194883A (en) 2004-06-04 2022-12-21 Genentech Inc Method for treating multiple sclerosis
CN101120020A (zh) * 2004-12-17 2008-02-06 健泰科生物技术公司 先前的疗法失败的患者中自身免疫病的抗血管发生疗法
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
CA2597924C (en) 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
EP2050763A3 (en) 2005-03-10 2009-07-15 Genentech, Inc. Methods and compositions for modulating vascular integrity
US7579381B2 (en) * 2005-03-25 2009-08-25 Edwards Lifesciences Corporation Treatment of bioprosthetic tissues to mitigate post implantation calcification
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2008073582A2 (en) 2006-10-27 2008-06-19 Edwards Lifesciences Corporation Biological tissue for surgical implantation
JP5575636B2 (ja) 2007-05-07 2014-08-20 メディミューン，エルエルシー 抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
US9101691B2 (en) 2007-06-11 2015-08-11 Edwards Lifesciences Corporation Methods for pre-stressing and capping bioprosthetic tissue
US9233107B2 (en) 2007-09-14 2016-01-12 Biogen Ma Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML)
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US8357387B2 (en) 2007-12-21 2013-01-22 Edwards Lifesciences Corporation Capping bioprosthetic tissue to reduce calcification
US20090252725A1 (en) * 2008-03-07 2009-10-08 Biogen Idec Ma Inc. Use of CD23 Antibodies to Treat Malignancies in Patients with Poor Prognosis
AU2009240564A1 (en) * 2008-04-25 2009-10-29 Allosource Anti-adhesion barrier wound dressing comprising processed amniotic tissue and method of use
US9358320B2 (en) 2008-04-25 2016-06-07 Allosource Multi-layer tissue patches
US9480549B2 (en) 2008-04-25 2016-11-01 Allosource Multi-layer tissue patches
ES2438496T3 (es) 2008-08-01 2014-01-17 Ventirx Pharmaceuticals, Inc. Formulaciones de agonistas de receptores de tipo toll y su uso
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
AU2009303304A1 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind TRAIL-RI and TRAIL-R2
CN102438652B (zh) 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2012001306A (es) 2009-07-31 2012-02-28 Genentech Inc Inhibicion de matastasis de tumor.
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
WO2011033006A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011043835A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
EP2674174B1 (en) 2010-03-23 2019-10-16 Edwards Lifesciences Corporation Methods of conditioning sheet bioprosthetic tissue
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US8906601B2 (en) 2010-06-17 2014-12-09 Edwardss Lifesciences Corporation Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
CN102946916B (zh) 2010-06-17 2015-03-18 爱德华兹生命科学公司 通过化学修饰抗原性碳水化合物稳定生物假体组织的方法
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
NZ608673A (en) 2010-10-01 2015-04-24 Univ Pennsylvania Therapeutic use of a tlr agonist and combination therapy
CN104998254A (zh) 2010-11-08 2015-10-28 基因技术公司 皮下施用的抗-il-6受体抗体
US9351829B2 (en) 2010-11-17 2016-05-31 Edwards Lifesciences Corporation Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
MX355255B (es) 2011-02-04 2018-04-11 Genentech Inc Variantes de fc y métodos para su producción.
US20120203254A1 (en) * 2011-02-07 2012-08-09 David Tak Wai Chiu Allogenic Vessel Nerve Conduit
RU2595836C2 (ru) 2011-03-31 2016-08-27 Дженентек, Инк. Способы введения антагонистов интегрина бета7
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9358107B2 (en) 2011-06-30 2016-06-07 Edwards Lifesciences Corporation Systems, dies, and methods for processing pericardial tissue
CA2839341C (en) 2011-07-04 2020-12-15 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
RU2014109985A (ru) 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
US9585983B1 (en) 2011-10-12 2017-03-07 BioDlogics, LLC Wound covering and method of preparation
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
CA2863066A1 (en) 2012-01-31 2013-08-08 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
AU2013221317B2 (en) 2012-02-16 2017-07-06 Pangu Biopharma Limited Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
JP6309002B2 (ja) 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
US10238771B2 (en) 2012-11-08 2019-03-26 Edwards Lifesciences Corporation Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system
US10905800B1 (en) 2013-01-29 2021-02-02 BioDlogics, LLC Ocular covering and method of use
CN105247072B (zh) 2013-02-25 2019-10-15 基因泰克公司 检测和治疗抗药性akt突变体的方法和组合物
US9498327B1 (en) 2013-03-05 2016-11-22 Biodlogics Llc Repair of tympanic membrane using human birth tissue material
US9789138B1 (en) 2013-03-06 2017-10-17 BioDlogics, LLC Neural repair construct and method of use
US9770472B1 (en) 2013-03-08 2017-09-26 Brahm Holdings, Llc Organ jacket and methods of use
US9855301B1 (en) 2013-03-13 2018-01-02 Biodlogics Llc Human birth tissue laminate and methods of use
US9682071B2 (en) 2013-03-15 2017-06-20 Intermune, Inc. Methods of improving microvascular integrity
US9795638B1 (en) 2013-03-16 2017-10-24 BioDlogics, LLC Cardiothoracic construct and methods of use
RU2015145610A (ru) 2013-03-27 2017-05-04 Дженентек, Инк. Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
US9615922B2 (en) 2013-09-30 2017-04-11 Edwards Lifesciences Corporation Method and apparatus for preparing a contoured biological tissue
US10959839B2 (en) 2013-10-08 2021-03-30 Edwards Lifesciences Corporation Method for directing cellular migration patterns on a biological tissue
CN106102767B (zh) 2014-03-27 2021-08-10 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
MX2016014409A (es) 2014-05-06 2017-01-20 Genentech Inc Produccion de proteinas heteromultimericas usando celulas de mamifero.
EA201790569A1 (ru) 2014-09-12 2017-08-31 Дженентек, Инк. Антитела и иммуноконъюгаты против cll-1
US10265438B1 (en) 2014-11-03 2019-04-23 BioDlogics, LLC Methods and compositions for the repair and replacement of connective tissue
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
JP6802158B2 (ja) 2014-12-05 2020-12-16 ジェネンテック， インコーポレイテッド 抗ＣＤ７９ｂ抗体及び使用方法
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2016138207A1 (en) 2015-02-26 2016-09-01 Genentech, Inc. Integrin beta7 antagonists and methods of treating crohn's disease
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
CA2996383A1 (en) 2015-08-25 2017-03-02 Nancy GUPTA Immunomodulatory compositions and methods of use thereof
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
LT3359572T (lt) 2015-10-06 2025-02-10 F. Hoffmann-La Roche Ag Išsėtinės sklerozės gydymo būdas
AU2016380988B2 (en) 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US10687934B2 (en) 2016-07-05 2020-06-23 Carlos A. Alvarado Serous membrane for ocular surface disorders
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045307A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CN110072519A (zh) 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
WO2018112255A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US11134889B2 (en) 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
KR20190095931A (ko) 2016-12-14 2019-08-16 프로제너티, 인크. 섭취가능한 디바이스를 사용하여 방출된 il-12/il-23 저해제로의 위장관 질환의 치료
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054156A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
US20210401895A1 (en) 2017-03-30 2021-12-30 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
CA3054159A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2018222434A1 (en) 2017-05-31 2018-12-06 Edwards Lifesciences Corporation Collagen fibers and articles formed therefrom
US20210128667A1 (en) 2017-08-23 2021-05-06 Kezar Life Sciences Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
EP3743124B1 (en) 2018-01-23 2024-05-08 Edwards Lifesciences Corporation Method for pre-stretching implantable biocompatible materials, and materials and devices produced thereby
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
JP7421504B2 (ja) 2018-06-01 2024-01-24 ビオラ・セラピューティクス・インコーポレイテッド 胃腸のマイクロバイオームの検出および操作のためのデバイスおよびシステム
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US11103619B2 (en) 2018-08-30 2021-08-31 Efstathios-Andreas AGATHOS Anticalcification treatment for impantable biological tissues using calcitonin
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
CN113164258B (zh) 2018-11-01 2024-08-27 爱德华兹生命科学公司 经导管再生肺动脉瓣
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
AU2019428629A1 (en) 2019-02-06 2021-01-28 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type I
BR112021019448A2 (pt) 2019-04-02 2021-11-30 Sangamo Therapeutics Inc Métodos para o tratamento de beta-talassemia
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
TW202330613A (zh) 2021-11-12 2023-08-01 美商建南德克公司 使用整聯蛋白β７拮抗劑治療克隆氏病之方法
WO2024127332A1 (en) 2022-12-14 2024-06-20 Pheon Therapeutics Ltd Cytotoxic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3057775A (en) * 1959-02-04 1962-10-09 Champion Co Embalming composition
US3974526A (en) * 1973-07-06 1976-08-17 Dardik Irving I Vascular prostheses and process for producing the same
US3988782A (en) * 1973-07-06 1976-11-02 Dardik Irving I Non-antigenic, non-thrombogenic infection-resistant grafts from umbilical cord vessels and process for preparing and using same

Also Published As

Publication number Publication date
IL47062A (en) 1979-07-25
JPS51124094A (en) 1976-10-29
US4120649A (en) 1978-10-17
FR2306707A1 (fr) 1976-11-05
GB1527152A (en) 1978-10-04
IL47062A0 (en) 1975-06-25
DE2614873A1 (de) 1976-10-21

Similar Documents

Publication Publication Date Title
FR2306707B1 (OSRAM)
AU1385876A (OSRAM)
JPS5195322A (OSRAM)
JPS5237574U (OSRAM)
JPS521005U (OSRAM)
JPS529628U (OSRAM)
JPS5610028Y2 (OSRAM)
JPS5517126Y2 (OSRAM)
JPS51132929U (OSRAM)
JPS51153514U (OSRAM)
CH588071A5 (OSRAM)
BG22431A1 (OSRAM)
CH601881A5 (OSRAM)
CH587550A5 (OSRAM)
CH585655A5 (OSRAM)
CH582441A5 (OSRAM)
CH472175A4 (OSRAM)
CH1545575A4 (OSRAM)
CH1422975A4 (OSRAM)
BG26729A1 (OSRAM)
BG22881A1 (OSRAM)
BG22739A1 (OSRAM)
CH597496A5 (OSRAM)
BG22301A1 (OSRAM)
BG22146A1 (OSRAM)

Legal Events

Date Code Title Description
ST Notification of lapse